Leerink Partnrs Estimates Innate Pharma Q3 Earnings

Key Points

• Leerink Partners forecasts Innate Pharma's Q3 2025 earnings to be ($0.14) per share, maintaining a "Hold" rating on the stock.
• The consensus target price for Innate Pharma is currently $6.50, with one analyst giving a "Buy" rating, while others have rated it as "Hold" or "Neutral."
• Innate Pharma's stock has experienced a 3.6% decline recently, with current trading at $1.87, well below its 52-week high of $3.51.

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Stock analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Innate Pharma in a research report issued on Wednesday, September 17th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings of ($0.14) per share for the quarter. Leerink Partnrs has a "Hold" rating on the stock. Leerink Partnrs also issued estimates for Innate Pharma's Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.15) EPS and Q2 2027 earnings at ($0.15) EPS.

IPHA has been the subject of several other reports. BTIG Research initiated coverage on shares of Innate Pharma in a research report on Monday, July 28th. They issued a "buy" rating for the company. Leerink Partners reissued a "market perform" rating and issued a $2.00 price target (down from $10.00) on shares of Innate Pharma in a report on Thursday. Finally, HC Wainwright downgraded shares of Innate Pharma from a "buy" rating to a "neutral" rating in a report on Thursday. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $6.50.

Innate Pharma Trading Down 2.1%

IPHA stock traded down $0.04 during trading hours on Monday, hitting $1.83. The company's stock had a trading volume of 11,669 shares, compared to its average volume of 15,241. The company has a debt-to-equity ratio of 3.52, a quick ratio of 2.60 and a current ratio of 2.21. Innate Pharma has a 12 month low of $1.29 and a 12 month high of $3.51. The stock has a 50 day moving average price of $2.06 and a two-hundred day moving average price of $2.02.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.